Cobas diagnostic test platform

Manufactured by Roche

The Cobas diagnostic test platform is an integrated system for automated in vitro diagnostic testing. It is designed to perform a range of laboratory analyses, including immunoassays and clinical chemistry tests. The Cobas platform provides automated sample handling, processing, and results reporting to support efficient and reliable diagnostic workflows.

Automatically generated - may contain errors

Lab products found in correlation

Anti s1 spike protein, by Roche (2 mentions) Anti nucleocapsid protein, by Roche (2 mentions)

4 protocols using cobas diagnostic test platform

SARS-CoV-2 Infection in Healthcare Workers

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

We undertook a case control study nested within our COVIDsortium health care worker cohort. Participant screening, study design, sample collection, and sample processing have been described in detail previously.⁶ (link)^,⁷ (link)^,⁹ (link)^,¹⁰ (link) Healthcare workers were recruited at St Bartholomew’s Hospital, London, UK in the week of lockdown in the United Kingdom (between 23^rd and 31^st March 2020). Participants underwent weekly evaluation using a questionnaire and biological sample collection (including serological assays) for up to 16 weeks when fit to attend work at each visit, with further follow up samples collected at 6 months. Participants with available blood RNA samples who had PCR-confirmed SARS-CoV-2 infection (Roche cobas diagnostic test platform) at any time point were included as ‘cases’. A subset of consecutively recruited participants without evidence of SARS-CoV-2 infection on nasopharyngeal swabs and who remained seronegative by both Euroimmun antiS1 spike protein and Roche anti-nucleocapsid protein throughout follow-up were included as uninfected controls. The baseline characteristics of the study participants are provided in Table S1.

Chandran A., Rosenheim J., Nageswaran G., Swadling L., Pollara G., Gupta R.K., Burton A.R., Guerra-Assunção J.A., Woolston A., Ronel T., Pade C., Gibbons J.M., Sanz-Magallon Duque De Estrada B., Robert de Massy M., Whelan M., Semper A., Brooks T., Altmann D.M., Boyton R.J., McKnight Á., Captur G., Manisty C., Treibel T.A., Moon J.C., Tomlinson G.S., Maini M.K., Chain B.M, & Noursadeghi M. (2022). Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections. Cell Reports Medicine, 3(3), 100557.

+ Open protocol

+ Expand

Longitudinal Study of COVID-19 in Healthcare Workers

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

We undertook a case control study nested within our COVID consortium healthcare worker cohort. Participant screening, study design, sample collection, and sample processing have been described in detail previously (21 (link)). Briefly, healthcare workers were recruited (between 23^rd and 31^st March 2020) and underwent weekly evaluation using a questionnaire and biological sample collection for up to 16 weeks when fit to attend work at each visit, with further follow up samples collected at 6 months.
Participants with available blood RNA samples who had PCR-confirmed SARS-COV-2 infection (Roche cobas^® diagnostic test platform) at any time point were included. A subset of consecutively recruited participants without evidence of SARS-COV-2 infection on nasopharyngeal swabs and who remained seronegative by both Euroimmun anti S1 spike protein and Roche anti-nucleocapsid protein throughout follow-up were included as uninfected controls.

Mark M., Reich-Zeliger S., Greenstein E., Biram A., Chain B., Friedman N, & Madi A. (2023). Viral infection reveals hidden sharing of TCR CDR3 sequences between individuals. Frontiers in Immunology, 14, 1199064.

+ Open protocol

+ Expand

COVID-19 Infection in Healthcare Workers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Healthcare workers were recruited at St Bartholomew’s Hospital, London, UK in the week of lockdown in the United Kingdom (between 23rd and 31st March 2020).³ (link) Participants underwent weekly evaluation using a questionnaire and biological sample collection (including serological assays) for up to 16 weeks when fit to attend work at each visit, with further follow up samples collected at 6 months. Participants with available blood RNA samples who had PCR-confirmed SARS-CoV-2 infection (Roche cobas diagnostic test platform) at any time point were included as ‘cases’. A subset of consecutively recruited participants without evidence of SARS-CoV-2 infection on nasopharyngeal swabs and who remained seronegative by both Euroimmun antiS1 spike protein and Roche anti-nucleocapsid protein throughout follow-up were included as uninfected controls.

Milighetti M., Peng Y., Tan C., Mark M., Nageswaran G., Byrne S., Ronel T., Peacock T., Mayer A., Chandran A., Rosenheim J., Whelan M., Yao X., Liu G., Felce S.L., Dong T., Mentzer A.J., Knight J.C., Balloux F., Greenstein E., Reich-Zeliger S., Pade C., Gibbons J.M., Semper A., Brooks T., Otter A., Altmann D.M., Boyton R.J., Maini M.K., McKnight A., Manisty C., Treibel T.A., Moon J.C., Noursadeghi M, & Chain B. (2023). Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection. iScience, 26(6), 106937.

+ Open protocol

+ Expand

COVID-19 Infection in Healthcare Workers

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

We undertook an unmatched case control study nested within our COVIDsortium health care worker cohort. Participant screening, study design, sample collection, and sample processing have been described in detail previously⁶ (link)^,8 (link), 9 (link), 10 and the study is registered at ClinicalTrials.gov (NCT04318314, first posted 23^rd March 2020: the date of first study member recruitment). Briefly, healthcare workers were recruited at St Bartholomew's Hospital, London, UK in the first week of lockdown in the United Kingdom (between 23^rd and 31^st March 2020). Participants underwent weekly evaluation using a questionnaire and biological sample collection (including PCR and serological assays) for up to 16 weeks when fit to attend work at each visit, with further follow up symptom questionnaires collected at 6 and 12 months. Participants with available plasma samples who had PCR-confirmed SARS-CoV-2 infection (Roche cobas® diagnostic test platform) at any time point from week 0 to week 6 were included as ‘cases’. A subset of consecutively recruited participants at baseline without evidence of SARS-CoV-2 infection on nasopharyngeal swabs and who remained seronegative by both Euroimmun antiS1 spike protein and Roche anti-nucleocapsid protein throughout follow-up were included as uninfected HCW.

Captur G., Moon J.C., Topriceanu C.C., Joy G., Swadling L., Hallqvist J., Doykov I., Patel N., Spiewak J., Baldwin T., Hamblin M., Menacho K., Fontana M., Treibel T.A., Manisty C., O'Brien B., Gibbons J.M., Pade C., Brooks T., Altmann D.M., Boyton R.J., McKnight Á., Maini M.K., Noursadeghi M., Mills K, & Heywood W.E. (2022). Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. eBioMedicine, 85, 104293.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!